Gene delivery to the nervous system represents perhaps the ultimate challenge of gene therapy in view of the complexity of this system, the wide variety of intractable neurological diseases, and the need to deliver the gene to nondividing cells. Although a variety of systems for such gene delivery are under development, herpes simplex virus has unique advantages in terms of its large genome size and its ability to naturally enter a latent state in neuronal cells. Considerable progress has been made in the effective disablement of this virus while retaining its ability to deliver genes and in producing long-term expression of the foreign gene. It is likely that these viruses may ultimately be of use in human gene therapy procedures for otherwise intractable neurological diseases such as Parkinson’s disease.
Ace CI, McKee TA, Ryan M, Cameron JM, Preston CM. 1989. Construction and characterisation of a herpes simplex virus type I mutant unable to transduce immediate-early gene expression. J Virol63:2260-2269.
2.
Amin V, Cumming DVE, Latchman DS. 1996. Over-expression of heat shock protein 70 protects neuronal cells against both thermal and ischaemic stress but with different efficiencies. Neurosci Lett206:45-48.
3.
Bencsjcs C, Wachtel SR, Milstien S, Hatakeyama K, Becker JB, Kang UJ. 1996. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of LDOPA by primary fibroblasts. J Neurosci16:4449-4456.
4.
Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert J-J, Mallet J, and others. 1997. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci94:8818-8823.
5.
Brar BS, Stephanou A, Wagstaff MJD, Coffin RS, Marber MS, Engelmann G, and others. 1999. Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or ischaemic stress. J Mol Cell Cardiol31:135-146.
6.
Chiocca AE, Choi BB, Cai W, DeLuca N, Schaffer PA, DiFiglia M, and others. 1990. Transfer and expression of the lac Z gene in rat brain neurons by herpes simplex virus mutants. New Biol266:739-746.
7.
Coffin RS, Howard MK, Cumming DVE, Dollery CM, McEwan J, Yellon DM, and others. 1996. Gene delivery to cardiac cells in vitro and in vivo using herpes simplex virus vectors. Gene Ther3:560-566.
8.
Coffin RS, Latchman DS. 1996. Herpes simplex virus based vectors. In: Latchman DS, editor. Genetic manipulation of the nervous system. New York: Academic Press. p 99-114.
9.
Coffin RS, Maclean AR, Latchman DS, Brown SM. 1996. Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors. Gene Ther3:886-891.
10.
Coffin RS, Thomas SK, Thomas NSB, Lilley CE, Pizzey AR, Griffiths CH, and others. 1998. Pure populations of transduced primary human cells can be produced using GFP expressing herpes virus vectors and flow cytometry. Gene Ther5:718-722.
11.
Croen KD, Ostrove JM, Dragovic LJ, Smialek JE, Straus SE. 1987. Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene anti-sense transcript by in situ hybridization. N Engl J Med317:1427-1432.
12.
Dobson AT, Margolis TP, Gomes WA, Feldman LT. 1995. In vivo deletion analysis of the herpes simplex virus type 1 latency associated transcript promoter. J Virol69:2264-2270.
During MJ, Naegele JR, O’Malley KL, Geller AI. 1994. Long-term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science266:1399-1403.
15.
Ensor E, Smith MD, Latchman DS. 2001. The Brn-3a transcription factor protects sensory but not sympathetic neurones from programmed cell death/apoptosis. J Biol Chem276:5204-5212.
16.
Fink DJ, DeLuca NA, Goins WF, Glorioso JC. 1996. Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci19:265-287.
17.
Fink DJ, Sternberg LR, Weber PC, Mata M, Goins WF, Glorioso JS. 1992. In vivo expression of β-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum Gene Ther3:11-19.
18.
Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH. 1991. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-Dopa. Neuron6:371-380.
19.
Freese A, Stern M, Kaplitt MG, O’Connor WM, Abbey MV, O’Connor MJ, During MJ. 1996. Prospects for gene therapy in Parkinson’s disease. Movement Dis11:469-488.
20.
French Anderson W. 1998. Human gene therapy. Nature392(Suppl):25-30.
21.
French Anderson W. 2000. Gene therapy scores against cancer. Nature Med6:862-863.
22.
Goding CR, O’Hare P. 1989. Herpes simplex virus Vmw65-octamer binding protein interaction: a paradigm for combinatorial control of transcription. Virology173:363-367.
23.
Goins WF, Stenberg LR, Croen KD, Krause PR, Hendricks RL, Fink DJ, and others. 1994. A novel latency-associated promoter is continued within the herpes simplex virus type 1 UL flanking repeats. J Virol68:2239-2252.
24.
Haase G, Kennel P, Pettmann B, Vigne E, Akli A, Revah F, and others. 1997. Gene therapy of murine motor neuron disease using aden-oviral vectors for neurotrophic factors. Nature Med3:429-436.
25.
Ho DY, Mocarski ES. 1988. B-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus infected mouse. Virology167:279-283.
26.
Ho DY, Mocarski ES. 1989. Herpes simplex virus latent RNA (Lat) is not required for latent infection in the mouse. Proc Natl Acad Sci U S A86:7596-7600.
27.
Horellou P, Vigne E, Castel MN, Barneoud P, Colin P, Perricaudet M, and others. 1994. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson’s disease. Neuroreport6:49-53.
28.
Howard MK, Kershaw T, Gibb B, Storey W, Maclean AR, Zeng B-W, and others. 1998. High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5. Gene Ther5:1137-1147.
29.
Huard J, Glorioso JC. 1995. Herpes simplex virus type 1 vector mediated gene transfer to muscle. Gene Ther2:385-392.
30.
Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O’Malley KL, and others. 1994. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet8:148-154.
31.
Kennedy GE. 1997. Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. Brain120:1245-1259.
32.
Lapchak PA. 1996. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev Neurosci7:165-176.
33.
Lapchak PA, Miller PJ, Jiao SS, Araujo DM, Hilt D, Collins R. 1996. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson’s disease. Neurodegeneration5:197-205.
34.
Latchman DS. 1990. Molecular biology of herpes simplex virus latency. Int J Exp Pathol71:133-141.
35.
Latchman DS. 1996. Genetic manipulation of the nervous system. New York: Academic Press.
36.
Latchman DS, Coffin RS. 2000. Viral vectors and Parkinson’s disease. Movement Dis15:9-17.
37.
Lindvall O, Brundin P, Widner H, Rhencrona S, Gustavii B, Fracowiak R, and others. 1996. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science247:574-577.
38.
Lokensgard JR, Bloom DC, Dobson AT, Feldman LT. 1994. Long term promoter activity during herpes simplex virus latency. J Virol68:7148-7158.
39.
Lu B, Gupta S, Federoff H. 1995. Ex vivo hepatic gene transfer in mouse using a defective herpes simplex virus-1 vector. Hepatology21:752-759.
40.
Maclean AR, Fareed MU, Robertson L, Harland J, Brown SM. 1991. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate-early gene 1 and the ‘a’ sequence. J Gen Virol72:631-639.
41.
Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Leff SE. 1998. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-Cyclohydrolase I in a rat model of Parkinson’s disease. J Neurosci18:4271-4284.
42.
Margolis TP, Bloom DC, Dobson AT, Feldman LT, Stevens JG. 1993. Decreased reporter gene expression during latent infection with HSV LAT promoter constructs. Virology197:585-592.
43.
Margolis TP, Sedarati F, Dobson AT, Feldman LT, Stevens JG. 1992. Pathways of viral gene expression during acute neuronal infection with HSV-1. Virology189:150-160.
44.
Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, and others. 2000. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther7:867-874.
45.
Miller AD. 1992. Human gene therapy comes of age. Nature357:455-460.
46.
Miller AG, Adam MA, Miller AD. 1990. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol10:4239-4242.
47.
Olanow CW, Kordower JH, Freeman TB. 1996. Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends Neurosci19:102-109.
48.
Palella TD, Silverman LJ, Schroll CT, Homa FL, Levine M, Kelley WN. 1988. Herpes simplex virus mediated human hypoxanthineguanine phosphoribosyl transferase gene transfer into neuronal cells. Mol Cell Biol8:457-460.
49.
Palmer J, Branston R, Lilley CE, Robinson M, Groutsi F, Smith J, and others. 2000. Development and optimisation of herpes simplex virus vectors for multiple long term gene delivery to the peripheral nervous system. J Virol74:5604-5618.
50.
Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, and others. 2000. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther7:859-866.
51.
Roizman B, Sears AE. 1987. An inquiry into the mechanisms of herpes simplex virus latency. Ann Rev Microbiol41:543-571.
52.
Sacks WR, Greene CC, Aschmann DP, Schaffer PA. 1985. Herpes simplex virus type 1 ICP27 is an essential regulatory protein. J Virol55:796-805.
53.
Senut M-C, Suhr ST, Gage FH. 1996. Transplantation of genetically modified non-neuronal cells in the central nervous system. In: Latchman DS, editor. Genetic manipulation of the nervous system. New York: Academic Press. p 181-202.
54.
Smith MD, Ensor EA, Coffin RS, Boxer LM, Latchman DS. 1998. Bcl-2 transcription from the proximal p2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor. J Biol Chem273:16715-16722.
55.
Smith MD, Melton LA, Ensor EA, Packham G, Anderson P, Kinloch RA, and others. 2001. Brn-3a activates the expression of Bcl-XL and promotes neuronal survival in vivo as well as in vitro. Mol Cell Neurosci. In press.
56.
Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. 1987. RNA complementary to a herpes virus alpha gene mRNA is prominent in latently infected neurons. Science235:1056-1059.
57.
Thomas SK, Lilley CE, Latchman DS, Coffin RS. 1999. Equine herpes virus 1 gene 12 can substitute for Vmw65 in the growth of herpes simplex virus 1 (HSV1) allowing the generation of optimised cell lines for the propagation of vectors with multiple immediate-early gene defects. J Virol73:7399-7409.
58.
Tsuda M, Imaokea T. 1996. Direct injection of plasmid DNA into the brain. In: Latchman DS, editor. Genetic manipulation of the nervous system. New York: Academic Press. p 235-248.
59.
Wagstaff MJD, Collaco-Moraes Y, Smith J, de Belleroche J, Coffin RS, Latchman DS. 1999. Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector. J Biol Chem274:5061-5069.
60.
Wang Q, Guo J, Jia W. 1997. Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. Gene Ther4:1300-1304.
61.
Widner H, Tetrud J, Rehncrona S. 1992. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med327:1556-1563.
62.
Wyatt S, Mailhos C, Latchman DS. 1996. Trigeminal ganglion neurons are protected by the heat shock proteins hsp70 and hsp90 from thermal stress but not from programmed cell death following NGF withdrawal. Brain Res39:52-56.
63.
Yamamura J, Kageyama S, Uwano T, Kurokawa M, Imakita M, Shiraki K. 2000. Long-term gene expression in the anterior horn motor neurons after intramuscular inoculation of a live herpes simplex virus vector. Gene Ther7:934-941.
